[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653063":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":27,"studyPopulation":20,"armGroups":28,"interventions":35,"overallOfficials":20,"centralContacts":41,"locations":50,"responsibleParty":68,"collaborators":20,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":20,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":20,"enrollmentInfo":80,"targetDuration":20,"studyType":83,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":53,"whyStopped":20,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Guilin Medical University, China","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Diagnostic efficacy","The sensitivity, specificity, and accuracy of standard-of-care imaging (FDG PET\u002FCT) and CD38 PET\u002FCT were calculated and compared to evaluate the diagnostic accuracy.","3 year",[14,17],{"measure":15,"description":16,"timeFrame":12},"Number of lesions","The numbers of positive primary and metastatic lesions of standard-of-care imaging (FDG PET\u002FCT) and CD38 PET\u002FCT were recorded by visual interpretation.",{"measure":18,"description":19,"timeFrame":12},"SUV","Standardized uptake value (SUV) of standard-of-care imaging (FDG PET\u002FCT) and CD38 PET\u002FCT for each target lesion of subject or suspected primary tumor or\u002Fand metastasis.",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE","CD38 targeting PET radiotracer is promising as an excellent imaging agent applicable to Multiple Myeloma. In this research, subjects with Multiple Myeloma or highly suspected recurrence detection underwent contemporaneous CD38 PET\u002FCT and standard-of-care imaging (FDG PET\u002FCT) either for an initial assessment or for metastases or highly suspected recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of positive tumor lesions of standard-of-care imaging and FDG PET\u002FCT were recorded by visual interpretation. The diagnostic accuracy of CD38 PET\u002FCT was calculated and compared to standard-of-care imaging.",[29],{"label":30,"type":31,"description":32,"interventionNames":33},"CD38 PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of radiolabeld CD38 and undergoes PET\u002FCT imaging within the specified time.",[34],"Diagnostic Test: standard-of-care imaging (FDG PET\u002FCT), CD38 PET\u002FCT",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":20},"DIAGNOSTIC_TEST","standard-of-care imaging (FDG PET\u002FCT), CD38 PET\u002FCT","Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET\u002FCT imaging within the specified time.",[30],[42,47],{"name":43,"role":44,"phone":45,"phoneExt":20,"email":46},"Xingyu Mu, M.D.","CONTACT","86 13347631119","muxingyu1992@hotmail.com",{"name":48,"role":44,"phone":20,"phoneExt":20,"email":49},"Wei Fu","fuwei19700513@163.com",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"The First Affliated Hospital of Guilin Medical University","RECRUITING","Guilin","Guangxi","541001","China","CN",{"type":60,"coordinates":61},"Point",[62,63],110.29639,25.28022,{"lat":63,"lon":62},[66],{"name":67,"role":44,"phone":45,"phoneExt":20,"email":46},"Xingyu Mu",{"type":69,"investigatorFullName":48,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Department of Nuclear Medicine","100653063","cd38-targeted--pet-ct-for-multiple-myeloma-100653063",false,"NCT07782944","CD38 Targeted -PET\u002F CT for Multiple Myeloma","Clinical Investigation of CD38-Targeted Molecular Imaging Probes in Multiple Myeloma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of Multiple Myeloma (supporting evidence may include MRI, CT, tumor markers, and pathology report);\n* Patients who had scheduled both standard-of-care imaging (FDG PET\u002FCT) and cd38 PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.","ALL","18 Years",{"count":81,"type":82},100,"ESTIMATED","INTERVENTIONAL",[22],"The objective of the study is to construct a noninvasive approach CD38 targeted PET\u002FCT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET\u002FCT.",[87],"Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma",[89,90,91,92],"CD38","PET\u002FCT","radiotracer","Multiple Myeloma","2026-08-20",{"date":95,"type":96},"2026-08-24","ACTUAL",{"date":98,"type":96},"2026-07-07",{"date":100,"type":82},"2030-12-31",{"name":5,"class":6},1]